{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:39:27Z","timestamp":1791823167070,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010511","name":"Clinical and Translational Science Institute, University of California, San Francisco","doi-asserted-by":"publisher","award":["UL1 TR000004"],"award-info":[{"award-number":["UL1 TR000004"]}],"id":[{"id":"10.13039\/100010511","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010511","name":"Clinical and Translational Science Institute, University of California, San Francisco","doi-asserted-by":"publisher","award":["UL1 TR000004"],"award-info":[{"award-number":["UL1 TR000004"]}],"id":[{"id":"10.13039\/100010511","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>In adults, intravenous (IV) dihydroergotamine (DHE) has been shown to be effective at improving medium term outcomes in patients with chronic headache disorders. The IV formulation is utilized given its superior bioavailability. We aim to assess the safety and effectiveness of repetitive IV DHE infusions paired with an adjustment of a preventive treatment strategy within children and youth with chronic headache disorders.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A retrospective chart review was conducted of children and youth diagnosed with a chronic headache disorder who were admitted for DHE from January 2014 \u2013 October 2020. Patients completed a 5-day, standardized protocol. A new preventive was started one week after discharge. Data were collected from pre- and post-admission clinic notes. Safety and tolerability were assessed. Results were evaluated using descriptive statistics and compared with paired <jats:italic>t<\/jats:italic>-tests.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>One hundred and eighty-seven patients were included for review. Sixty-eight percent (127) had chronic migraine (CM), 20% (37) new daily persistent headache (NDPH) and 12% (23) persistent headache attributed to head trauma (PHHT). The median (range) age was 16\u00a0years (7\u201321), and median (range) number of previous preventive trials was 4 (0\u201321). At follow-up, patients with CM had a significant decrease in headache days per month from 28.6 to 26.3\u00a0days (95% CI -4.1 to -1.3) <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, baseline headache intensity decreased from 5.9\/10 to 5.3\/10 (95% CI -1.3 to -0.1) <jats:italic>p<\/jats:italic>\u2009=\u20090.006, number of severe headache days per month decreased from 11.5 to 7.9\u00a0days (95% CI -6.5 to -2.3), <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, and monthly days of acute medication use from 12.1 to 9.8\u00a0days (95% CI -4.5 to -0.7) <jats:italic>p<\/jats:italic>\u2009=\u20090.002. In patients with NDPH there were significant decreases in baseline headache intensity from 6.4\/10 to 5.3\/10 (95% CI -1.7 to -0.3) <jats:italic>p<\/jats:italic>\u2009=\u20090.005 and monthly days of acute medication usage from 9.2\u00a0days to 5.9\u00a0days (95% CI -7.8 to -0.1) <jats:italic>p<\/jats:italic>\u2009=\u20090.043. Patients with PHHT had a significant decrease in headache days per month from 29 to 24\u00a0days (95% CI -9.4 to -0.7) <jats:italic>p<\/jats:italic>\u2009=\u20090.031. The most common side effects were nausea (85%) and mild leg cramping (60%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Repetitive DHE infusions followed by preventive treatment adjustment was well tolerated and significantly reduced headache frequency, baseline intensity, number of severe days and\/or acute medication usage in children and youth with refractory headache disorders.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s10194-025-02035-x","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T22:03:07Z","timestamp":1745964187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Tolerability of repetitive dihydroergotamine infusions paired with an adjustment in preventive treatment strategy in chronic headache disorders in children and youth"],"prefix":"10.1186","volume":"26","author":[{"given":"Sara","family":"Pavitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Vayngortin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Zorrilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengshi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy A.","family":"Gelfand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"issue":"10","key":"2035_CR1","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1177\/0333102411410610","volume":"31","author":"KA Payne","year":"2011","unstructured":"Payne KA, Varon SF, Kawata AK et al (2011) The International Burden of Migraine Study (IBMS): Study design, methodology, and baseline cohort characteristics. Cephalalgia 31(10):1116\u20131130. https:\/\/doi.org\/10.1177\/0333102411410610","journal-title":"Cephalalgia"},{"issue":"5","key":"2035_CR2","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1526-4610.2011.01885.x","volume":"51","author":"RB Lipton","year":"2011","unstructured":"Lipton RB, Manack A, Ricci JA, Chee E, Turkel CC, Winner P (2011) Prevalence and burden of chronic migraine in adolescents: results of the chronic daily headache in adolescents study (C-dAS). Headache 51(5):693\u2013706. https:\/\/doi.org\/10.1111\/j.1526-4610.2011.01885.x","journal-title":"Headache"},{"issue":"1","key":"2035_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1468-2982.2008.01693.x","volume":"29","author":"D Kernick","year":"2009","unstructured":"Kernick D, Campbell J (2009) Measuring the Impact of Headache in Children: A Critical Review of the Literature. Cephalalgia 29(1):3\u201316. https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01693.x","journal-title":"Cephalalgia"},{"issue":"4","key":"2035_CR4","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","volume":"37","author":"RC Burch","year":"2019","unstructured":"Burch RC, Buse DC, Lipton RB (2019) Migraine: Epidemiology, Burden, and Comorbidity. Neurol Clin 37(4):631\u2013649. https:\/\/doi.org\/10.1016\/j.ncl.2019.06.001","journal-title":"Neurol Clin"},{"key":"2035_CR5","doi-asserted-by":"publisher","unstructured":"Schulman EA, Lake III AE, Goadsby PJ, et al. Defining Refractory Migraine and Refractory Chronic Migraine: Proposed Criteria From the Refractory Headache Special Interest Section of the American Headache Society. Headache: The Journal of Head and Face Pain. 2008;48(6):778\u2013782. https:\/\/doi.org\/10.1111\/j.1526-4610.2008.01132.x","DOI":"10.1111\/j.1526-4610.2008.01132.x"},{"key":"2035_CR6","doi-asserted-by":"publisher","unstructured":"Winner P, Pearlman EM, Linder SL, Jordan DM, Fisher AC, Hulihan J. Topiramate for Migraine Prevention in Children: A Randomized, Double-Blind, Placebo-Controlled Trial. Headache: The Journal of Head and Face Pain. 2005;45(10):1304\u20131312. https:\/\/doi.org\/10.1111\/j.1526-4610.2005.00262.x","DOI":"10.1111\/j.1526-4610.2005.00262.x"},{"key":"2035_CR7","doi-asserted-by":"publisher","unstructured":"Silberstein SD, McCrory DC. Ergotamine and Dihydroergotamine: History, Pharmacology, and Efficacy. Headache: The Journal of Head and Face Pain. 2003;43(2):144\u2013166. https:\/\/doi.org\/10.1046\/j.1526-4610.2003.03034.x","DOI":"10.1046\/j.1526-4610.2003.03034.x"},{"issue":"11","key":"2035_CR8","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/0028-3908(91)90165-8","volume":"30","author":"MG Buzzi","year":"1991","unstructured":"Buzzi MG, Carter WB, Shimizu T, Heath H, Moskowitz MA (1991) Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 30(11):1193\u20131200. https:\/\/doi.org\/10.1016\/0028-3908(91)90165-8","journal-title":"Neuropharmacology"},{"key":"2035_CR9","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2147\/JPR.S203650","volume":"13","author":"R Shafqat","year":"2020","unstructured":"Shafqat R, Flores-Montanez Y, Delbono V, Nahas SJ (2020) Updated Evaluation of IV Dihydroergotamine (DHE) for Refractory Migraine: Patient Selection and Special Considerations. J Pain Res 13:859\u2013864. https:\/\/doi.org\/10.2147\/JPR.S203650","journal-title":"J Pain Res"},{"issue":"20","key":"2035_CR10","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1212\/WNL.0b013e3182377dbb","volume":"77","author":"AJ Nagy","year":"2011","unstructured":"Nagy AJ, Gandhi S, Bhola R, Goadsby PJ (2011) Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology 77(20):1827\u20131832. https:\/\/doi.org\/10.1212\/WNL.0b013e3182377dbb","journal-title":"Neurology"},{"issue":"10","key":"2035_CR11","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/j.1526-4610.1994.hed3410578.x","volume":"34","author":"SL Linder","year":"1994","unstructured":"Linder SL (1994) Treatment of Childhood Headache with Dihydroergotamine Mesylate. Headache 34(10):578\u2013580. https:\/\/doi.org\/10.1111\/j.1526-4610.1994.hed3410578.x","journal-title":"Headache"},{"key":"2035_CR12","doi-asserted-by":"publisher","unstructured":"Kabbouche MA, Powers SW, Segers A, et al. Inpatient Treatment of Status Migraine With Dihydroergotamine in Children and Adolescents. Headache: The Journal of Head and Face Pain. 2009;49(1):106\u2013109. https:\/\/doi.org\/10.1111\/j.1526-4610.2008.01293.x","DOI":"10.1111\/j.1526-4610.2008.01293.x"},{"key":"2035_CR13","doi-asserted-by":"publisher","unstructured":"Srouji R, Schenkel SR, Forbes P, Cahill JE. Dihydroergotamine infusion for pediatric refractory headache: A retrospective chart review. Headache: The Journal of Head and Face Pain. 2021;61(5):777\u2013789. https:\/\/doi.org\/10.1111\/head.14117","DOI":"10.1111\/head.14117"},{"issue":"9","key":"2035_CR14","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1212\/WNL.0000000000002406","volume":"86","author":"M Eller","year":"2016","unstructured":"Eller M, Gelfand AA, Riggins NY, Shiboski S, Schankin C, Goadsby PJ (2016) Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome. Neurology 86(9):856\u2013859. https:\/\/doi.org\/10.1212\/WNL.0000000000002406","journal-title":"Neurology"},{"issue":"Suppl 4","key":"2035_CR15","doi-asserted-by":"publisher","first-page":"S171","DOI":"10.1111\/j.1526-4610.2006.00601.x","volume":"46","author":"JR Saper","year":"2006","unstructured":"Saper JR, Silberstein S (2006) Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache 46(Suppl 4):S171-181. https:\/\/doi.org\/10.1111\/j.1526-4610.2006.00601.x","journal-title":"Headache"},{"issue":"18","key":"2035_CR16","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1517\/14656566.2010.533839","volume":"11","author":"JA Morren","year":"2010","unstructured":"Morren JA, Galvez-Jimenez N (2010) Where is dihydroergotamine mesylate in the changing landscape of migraine therapy? Expert Opin Pharmacother 11(18):3085\u20133093. https:\/\/doi.org\/10.1517\/14656566.2010.533839","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"2035_CR17","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1212\/WNL.0000000000004108","volume":"89","author":"AR Tso","year":"2017","unstructured":"Tso AR, Patniyot IR, Gelfand AA, Goadsby PJ (2017) Increased rate of venous thrombosis may be associated with inpatient dihydroergotamine treatment. Neurology 89(3):279\u2013283. https:\/\/doi.org\/10.1212\/WNL.0000000000004108","journal-title":"Neurology"},{"key":"2035_CR18","doi-asserted-by":"publisher","unstructured":"Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24 Suppl 1:9\u2013160. https:\/\/doi.org\/10.1111\/j.1468-2982.2003.00824.x","DOI":"10.1111\/j.1468-2982.2003.00824.x"},{"key":"2035_CR19","unstructured":"Gobel H. ICHD-3 The International Classification of Headache Disorders 3rd edition. ICHD-3 The International Classification of Headache Disorders 3rd edition. Accessed July 15, 2020. https:\/\/ichd-3.org\/"},{"issue":"6","key":"2035_CR20","doi-asserted-by":"publisher","first-page":"e1542","DOI":"10.1542\/peds.2010-1410","volume":"127","author":"AL Baxter","year":"2011","unstructured":"Baxter AL, Watcha MF, Baxter WV, Leong T, Wyatt MM (2011) Development and validation of a pictorial nausea rating scale for children. Pediatrics 127(6):e1542-1549. https:\/\/doi.org\/10.1542\/peds.2010-1410","journal-title":"Pediatrics"},{"issue":"2","key":"2035_CR21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377\u2013381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010","journal-title":"J Biomed Inform"},{"issue":"10","key":"2035_CR22","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/j.1468-2982.2004.00757.x","volume":"24","author":"A Hershey","year":"2004","unstructured":"Hershey A, Powers S, Vockell AL, LeCates S, Segers A, Kabbouche M (2004) Development of a Patient-Based Grading Scale for PedMIDAS. Cephalalgia 24(10):844\u2013849. https:\/\/doi.org\/10.1111\/j.1468-2982.2004.00757.x","journal-title":"Cephalalgia"},{"issue":"8","key":"2035_CR23","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1111\/head.13937","volume":"60","author":"LM Theroux","year":"2020","unstructured":"Theroux LM, Cappa R, Mendoza A, Mallawaarachchi I, Samanta D, Goodkin HP (2020) Implementation of an Intravenous Dihydroergotamine Protocol for Refractory Migraine in Children. Headache 60(8):1653\u20131663. https:\/\/doi.org\/10.1111\/head.13937","journal-title":"Headache"},{"issue":"7","key":"2035_CR24","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1212\/wnl.36.7.995","volume":"36","author":"NH Raskin","year":"1986","unstructured":"Raskin NH (1986) Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 36(7):995\u2013997. https:\/\/doi.org\/10.1212\/wnl.36.7.995","journal-title":"Neurology"},{"issue":"4","key":"2035_CR25","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/j.1526-4610.1986.hed2604168.x","volume":"26","author":"M Callaham","year":"1986","unstructured":"Callaham M, Raskin N (1986) A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache 26(4):168\u2013171. https:\/\/doi.org\/10.1111\/j.1526-4610.1986.hed2604168.x","journal-title":"Headache"},{"issue":"5","key":"2035_CR26","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40263-013-0061-2","volume":"27","author":"SD Silberstein","year":"2013","unstructured":"Silberstein SD, Kori SH (2013) Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine. CNS Drugs 27(5):385\u2013394. https:\/\/doi.org\/10.1007\/s40263-013-0061-2","journal-title":"CNS Drugs"},{"key":"2035_CR27","doi-asserted-by":"publisher","unstructured":"Wang VS, Kosman J, Yuan H, et al. Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: A retrospective study. Headache: The Journal of Head and Face Pain. 2023;63(9):1251\u20131258. https:\/\/doi.org\/10.1111\/head.14636","DOI":"10.1111\/head.14636"},{"key":"2035_CR28","unstructured":"ergot-derivatives-article-31-referral-restrictions-use-medicines-containing-ergot-derivatives_en.pdf. Accessed March 12, 2025. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/ergot-derivatives-article-31-referral-restrictions-use-medicines-containing-ergot-derivatives_en.pdf-0"},{"issue":"1","key":"2035_CR29","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/S0885-3924(02)00411-6","volume":"24","author":"N Katz","year":"2002","unstructured":"Katz N (2002) The Impact of Pain Management on Quality of Life. J Pain Symptom Manage 24(1):S38\u2013S47. https:\/\/doi.org\/10.1016\/S0885-3924(02)00411-6","journal-title":"J Pain Symptom Manage"},{"issue":"7","key":"2035_CR30","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1002\/ejp.1398","volume":"23","author":"P Vartiainen","year":"2019","unstructured":"Vartiainen P, Heiskanen T, Sintonen H, Roine RP, Kalso E (2019) Health-related quality of life change in patients treated at a multidisciplinary pain clinic. Eur J Pain 23(7):1318\u20131328. https:\/\/doi.org\/10.1002\/ejp.1398","journal-title":"Eur J Pain"},{"issue":"23","key":"2035_CR31","doi-asserted-by":"publisher","first-page":"e2347","DOI":"10.1212\/WNL.0000000000200292","volume":"98","author":"C Morris","year":"2022","unstructured":"Morris C, Ross A, Greene K, Irwin S, Wagstaff A, Gelfand A (2022) Outcomes That Matter to Adolescents With Continuous Headache Due to Chronic Migraine and Their Parents: A Pilot Survey Study. Neurology 98(23):e2347\u2013e2355. https:\/\/doi.org\/10.1212\/WNL.0000000000200292","journal-title":"Neurology"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02035-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02035-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02035-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T22:03:13Z","timestamp":1745964193000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-025-02035-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2035"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02035-x","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the University of California San Francisco Institutional Review Board as part of a standing approval for chart review research on pediatric headache disorders (16\u201318622). The need for written informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Sara Pavitt is a site PI on a clinical trial investigating rimegepant as an acute treatment in pediatric patients migraine. She is a site SubI investigating ubrogepant as an acute treatment in pediatric patients with migraine. She receives no salary support from these trials. She is a site PI for PICORI funded REACH study in which she does receive salary support. Cynthia Morris \u2013 No disclosuresLauren Shin \u2013 No disclosuresAndrew Jones \u2013 No disclosuresBeata Vayngortin \u2013 No disclosuresNatalia Zorrilla \u2013 No disclosuresChengshi Jin \u2013 No disclosures Isabel Allen \u2013 No disclosuresAmy A. Gelfand: In the last 24 months, Dr. Gelfand has received royalties from UpToDate (for authorship), and honoraria from Elsevier (for authorship), the American Academy of Neurology (for editing) the Taiwan Headache Society (for speaking) and the Weill Cornell Neurology Department (for speaking). She receives a stipend from the American Headache Society for her role as Editor of Headache. She receives grant support from PCORI as a member of the Steering Committee for the REACH study and from the UCSF Resource Allocation Program as an investigator","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"93"}}